Urol. praxi. 2019;20(5):214-218
New treatment options in hormone-sensitive prostate cancer
- Urologická klinika VFN a 1. LF UK v Praze
The main aim of the treatment of metastatic prostate cancer (mPC) is to lower the value of testosterone to the castration level. Androgen deprivation therapy (ADT) leads initially to a reduction of the level of prostate–specific antigen and/or to radiographic and clinical response. The combination of docetaxel chemotherapy or new hormone agents (abiraterone acetate, enzalutamide, apalutamide, darolutamide) in the first line treatment of mPC may lead to an increase in overall survival or time to radiographic progression. This article assesses the results of available studies and in conclusion it reviews which combination is the most appropriate for individual patient. We also recommend to read, among others, the last paragraph of this publication, which deals with the choice of appropriate first–line mPC medications.
Keywords: metastatic hormone-sensitive prostate cancer, docetaxel, abiraterone, enzalutamide, darolutamide, apalutamide
Published: December 1, 2019 Show citation
